63 related articles for article (PubMed ID: 26236801)
1. Dose-dense Temozolomide: Is It Still Promising?
Nagane M
Neurol Med Chir (Tokyo); 2015; 55 Suppl 1():38-49. PubMed ID: 26236801
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense temozolomide: is it still promising?
Nagane M
Neurol Med Chir (Tokyo); 2015; 55(1):38-49. PubMed ID: 25744349
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Garcia CR; Slone SA; Morgan RM; Gruber L; Kumar SS; Lightner DD; Villano JL
Med Oncol; 2018 Aug; 35(10):136. PubMed ID: 30155806
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.
Mallick S; Gandhi AK; Rath GK
Indian J Med Paediatr Oncol; 2015; 36(4):229-37. PubMed ID: 26811592
[TBL] [Abstract][Full Text] [Related]
5. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.
Omar AI; Mason WP
Core Evid; 2010 Jun; 4():93-111. PubMed ID: 20694068
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
Khasraw M; Ameratunga M; Grommes C
Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.
Suryadevara CM; Desai R; Abel ML; Riccione KA; Batich KA; Shen SH; Chongsathidkiet P; Gedeon PC; Elsamadicy AA; Snyder DJ; Herndon JE; Healy P; Archer GE; Choi BD; Fecci PE; Sampson JH; Sanchez-Perez L
Oncoimmunology; 2018; 7(6):e1434464. PubMed ID: 29872570
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.
Weathers SP; Rood-Breithaupt J; de Groot J; Thomas G; Manfrini M; Penas-Prado M; Puduvalli VK; Zwingelstein C; Yung WKA
Neurooncol Adv; 2021; 3(1):vdab141. PubMed ID: 34693288
[TBL] [Abstract][Full Text] [Related]
10. Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts.
Nishri Y; Vatarescu M; Luz I; Epstein L; Dumančić M; Del Mare S; Shai A; Schmidt M; Deutsch L; Den RB; Kelson I; Keisari Y; Arazi L; Cooks T; Domankevich V
Front Oncol; 2022; 12():888100. PubMed ID: 36237307
[TBL] [Abstract][Full Text] [Related]
11. Treatment options in newly diagnosed glioblastoma.
Lee EQ; Nayak L; Wen PY; Reardon DA
Curr Treat Options Neurol; 2013 Jun; 15(3):281-8. PubMed ID: 23553038
[TBL] [Abstract][Full Text] [Related]
12. Future directions in glioblastoma therapy.
Colman H
Am Soc Clin Oncol Educ Book; 2012; ():108-11. PubMed ID: 24451718
[TBL] [Abstract][Full Text] [Related]
13. Establishing the standard of care for patients with newly diagnosed and recurrent glioblastoma.
Gilbert MR
Am Soc Clin Oncol Educ Book; 2012; ():112-7. PubMed ID: 24451719
[TBL] [Abstract][Full Text] [Related]
14. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.
Robins HI; Eickhoff J; Gilbert MR; Armstrong TS; Shi W; De Groot JF; Schultz CJ; Hunter GK; Valeinis E; Roach M; Youssef EF; Souhami L; Howard SP; Lieberman FS; Herman JG; Zhang P; Mehta MP
Neurooncol Pract; 2019 Dec; 6(6):473-478. PubMed ID: 31832217
[TBL] [Abstract][Full Text] [Related]
15. The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
Patel MA; Kim JE; Ruzevick J; Li G; Lim M
Cancers (Basel); 2014 Sep; 6(4):1953-85. PubMed ID: 25268164
[TBL] [Abstract][Full Text] [Related]
16. New agents targeting angiogenesis in glioblastoma.
Timotheadou E
Chemother Res Pract; 2011; 2011():878912. PubMed ID: 22295207
[TBL] [Abstract][Full Text] [Related]
17. Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Carvalho BF; Fernandes AC; Almeida DS; Sampaio LV; Costa A; Caeiro C; Osório L; Castro L; Linhares P; Damasceno M; Vaz RC
Oncol Res Treat; 2015; 38(7-8):348-54. PubMed ID: 26278578
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):136-43. PubMed ID: 26256461
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
